Literature DB >> 17409140

Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.

Xiugen Zhang1, Farah Cassis-Ghavami, Mike Eller, Jeff Currier, Bonnie M Slike, Xuemin Chen, James Tartaglia, Mary Marovich, Paul Spearman.   

Abstract

Recombinant poxvirus vectors are undergoing intensive evaluation as vaccine candidates for a variety of infectious pathogens. Avipoxviruses, such as canarypox virus, are replication deficient in mammalian cells by virtue of a poorly understood species-specific restriction. Highly attenuated vaccinia virus strains such as modified vaccinia virus Ankara (MVA) are similarly unable to complete replication in most mammalian cells but have an abortive-late phenotype, in that the block to replication occurs post-virus-specific DNA replication. In this study, an identical expression cassette for human immunodeficiency virus gag, pro, and env coding sequences was placed in canarypox virus and MVA vector backbones in order to directly compare vector-borne expression and to analyze differences in vector-host cell interactions. Antigen production by recombinant MVA was shown to be greater than that from recombinant canarypox virus in the mammalian cell lines and in the primary human cells tested. This observation was primarily due to a longer duration of antigen production in recombinant MVA-infected cells. Apoptosis induction was found to be more profound with the empty canarypox virus vector than with MVA. Remarkably, however, the inclusion of a gag/pro/env expression cassette altered the kinetics of apoptosis induction in recombinant MVA-infected cells to levels equal to those found in canarypox virus-infected cells. Antigen production by MVA was noted to be greater in human dendritic cells and resulted in enhanced T-cell stimulation in an in vitro antigen presentation assay. These results reveal differences in poxvirus vector-host cell interactions that should be relevant to their use as immunization vehicles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409140      PMCID: PMC1933324          DOI: 10.1128/JVI.02654-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation.

Authors:  J Reimann; R Schirmbeck
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

2.  Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

Authors:  Kalpana Gupta; Michael Hudgens; Lawrence Corey; M Juliana McElrath; Kent Weinhold; David C Montefiori; Geoffrey J Gorse; Sharon E Frey; Michael C Keefer; Thomas G Evans; Raphael Dolin; David H Schwartz; Clayton Harro; Barney Graham; Paul W Spearman; Mark Mulligan; Paul Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2002-03-01       Impact factor: 3.731

Review 3.  Poxviruses and apoptosis: a time to die.

Authors:  Helen Everett; Grant McFadden
Journal:  Curr Opin Microbiol       Date:  2002-08       Impact factor: 7.934

4.  Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.

Authors:  Mary A Marovich; John R Mascola; Michael A Eller; Mark K Louder; Pierre A Caudrelier; Raphaelle El-Habib; Silvia Ratto-Kim; Josephine H Cox; Jeffrey R Currier; Bruce L Levine; Carl H June; Wendy B Bernstein; Merlin L Robb; Beatrice Schuler-Thurner; Ralph M Steinman; Deborah L Birx; Sarah Schlesinger-Frankel
Journal:  J Infect Dis       Date:  2002-10-07       Impact factor: 5.226

5.  Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

Authors:  R B Belshe; C Stevens; G J Gorse; S Buchbinder; K Weinhold; H Sheppard; D Stablein; S Self; J McNamara; S Frey; J Flores; J L Excler; M Klein; R E Habib; A M Duliege; C Harro; L Corey; M Keefer; M Mulligan; P Wright; C Celum; F Judson; K Mayer; D McKirnan; M Marmor; G Woody
Journal:  J Infect Dis       Date:  2001-04-10       Impact factor: 5.226

6.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion.

Authors:  R Ignatius; M Marovich; E Mehlhop; L Villamide; K Mahnke; W I Cox; F Isdell; S S Frankel; J R Mascola; R M Steinman; M Pope
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.

Authors:  D H Barouch; S Santra; M J Kuroda; J E Schmitz; R Plishka; A Buckler-White; A E Gaitan; R Zin; J H Nam; L S Wyatt; M A Lifton; C E Nickerson; B Moss; D C Montefiori; V M Hirsch; N L Letvin
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells.

Authors:  Z Y Fang; K Limbach; J Tartaglia; J Hammonds; X Chen; P Spearman
Journal:  Virology       Date:  2001-12-20       Impact factor: 3.616

10.  The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis.

Authors:  M Carmen Sancho; Sibylle Schleich; Gareth Griffiths; Jacomine Krijnse-Locker
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more
  15 in total

1.  Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo.

Authors:  C Cubillos-Zapata; E Guzman; A Turner; S C Gilbert; H Prentice; J C Hope; B Charleston
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.

Authors:  Samantha Brandler; Alice Lepelley; Marion Desdouits; Florence Guivel-Benhassine; Pierre-Emmanuel Ceccaldi; Yves Lévy; Olivier Schwartz; Arnaud Moris
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

Authors:  Corinna La Rosa; Jeff Longmate; Joy Martinez; Qiao Zhou; Teodora I Kaltcheva; Weimin Tsai; Jennifer Drake; Mary Carroll; Felix Wussow; Flavia Chiuppesi; Nicola Hardwick; Sanjeet Dadwal; Ibrahim Aldoss; Ryotaro Nakamura; John A Zaia; Don J Diamond
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

4.  Cowpox virus inhibits human dendritic cell immune function by nonlethal, nonproductive infection.

Authors:  Spencer J Hansen; John Rushton; Alexander Dekonenko; Hitendra S Chand; Gwyneth K Olson; Julie A Hutt; David Pickup; C Rick Lyons; Mary F Lipscomb
Journal:  Virology       Date:  2011-02-21       Impact factor: 3.616

5.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

6.  Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Authors:  José Luis Nájera; Carmen Elena Gómez; Juan García-Arriaza; Carlos Oscar Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

Review 7.  Nonreplicating vectors in HIV vaccines.

Authors:  Jennifer A Johnson; Dan H Barouch; Lindsay R Baden
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

8.  Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Authors:  Samuel O Pine; James G Kublin; Scott M Hammer; Joleen Borgerding; Yunda Huang; Danilo R Casimiro; M Juliana McElrath
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

9.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

10.  A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.

Authors:  Z Wang; W Zhou; T Srivastava; C La Rosa; A Mandarino; S J Forman; J A Zaia; W J Britt; D J Diamond
Journal:  Virology       Date:  2008-06-05       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.